学术会议

2015年ASCO上，关于中国正在进行中的中国人群的肺癌早期检测自身抗体谱检测的研究发布

对中国人群的肺癌早期检测自身抗体谱检测

Validation of autoantibody panel for early detection of lung cancer in Chinese population

Shengxiang Ren, Shucai Zhang, Zhiyong Ma, HouRong Cai, Xiaohong Xu, Jing Zhou, Xiaopeng Liu, Xuejun Hu, Caicun Zhou; Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China; Henan Cancer Hospital, Zhengzhou, China; Nanjing Drum Tower Hospital, Nanjing, China; Zhejiang Cancer Hospital, Hangzhou, China; Hangzhou CancerProbe Biotechnology Company, Hangzhou, China; Hangzhou CancerProbe Biotechnology Company, Hangzhou, China, Hangzhou, China; Shanghai Pulmonary Hospital, Shanghai, China

Abstract Text:

Background: Autoantibodies is an attractive diagnostic approach for early detection of malignant tumors. Our previous studies found a panel of 7 TAAs(p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4-5) was associated with lung cancer. We performed this large-scale, multi-center clinical trial to validate their ability to aid early diagnosis of lung cancer in Chinese population.

Methods:

The 7 TAAs were selected from 43 candidate TAAs from our previous studies, which were detected by ELISA in 1915 participants from 5 clinical centers in China. These samples including lung cancer (n = 818), benign lung diseases (n = 386), healthy volunteers (n = 415) and interference group (n = 296). The sensitivity and specificity from 7 TAAs and the traditional cancer biomarkers CEA, NSE and CYFRA21-1 were compared.

Results:

The sensitivity and specificity of autoantibody assay were 61% and 90% respectively, which were similar in different subgroups such as age, gender, smoker status and histological type. As for the enrolled patients with lung cancer, the sensitivities were 60% for patients with stage I/II, which were significantly higher than 27% ( p < 0.01)when using the combination of CEA, NSE and CYFRA21-1 to detect patients with lung cancer. While in patients with stage III/IV lung cancer, sensitivities were similar (63% vs. 56%, p > 0.05) and specificity was significantly improved (90% vs 71%, p < 0.01). The specificity was consistent in benign lung diseases and autoimmune diseases(interference group) and were 90% and 94% respectively and a concentration decrease of 7 TAAs were also observed after tumor resection.

Conclusions:

This study suggest that the 7 TAAs autoantibody panel can be used to aid diagnosis of lung cancer, and show a significantly improving sensitivity in patients with early stage lung cancer when comparing with the combination of CEA, NSE and CYFRA21-1.

学术交流